Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Parkin

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
The Journal of Infectious Diseases|May 6, 1999
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcomeS G Deeks, N S Hellmann, R M Grant, et al.
Journal of Virology|February 23, 2007
Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding regionCristina Villena, Julia G Prado, Maria Carmen Puertas, et al.
AIDS (London, England)|January 12, 2001
Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patientsN T Parkin, S G Deeks, M T Wrin, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2007
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor proteinEdward T Parkin, Nicole T Watt, Ishrut Hussain, et al.
The Journal of Infectious Diseases|December 7, 2019
Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical ImpactHerbert A Mbunkah, Silvia Bertagnolio, Raph L Hamers, et al.
Journal of Virology|March 21, 2008
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infectionSusan J Little, Simon D W Frost, Joseph K Wong, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1C J Petropoulos, N T Parkin, K L Limoli, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavirZehava Grossman, Ellen E Paxinos, Diana Averbuch, et al.
Scientific Reports|May 29, 2024
Kinetics of SARS-CoV-2 infection biomarkers in a household transmission studyAna M Groh, Maria J G T Vehreschild, Damian Diaz, et al.
Journal of Virology|May 18, 2007
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populationsWei Huang, Susan H Eshleman, Jonathan Toma, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
The Journal of Infectious Diseases|May 6, 1999
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcomeS G Deeks, N S Hellmann, R M Grant, et al.
Journal of Virology|February 23, 2007
Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding regionCristina Villena, Julia G Prado, Maria Carmen Puertas, et al.
AIDS (London, England)|January 12, 2001
Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patientsN T Parkin, S G Deeks, M T Wrin, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 19, 2007
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor proteinEdward T Parkin, Nicole T Watt, Ishrut Hussain, et al.
The Journal of Infectious Diseases|December 7, 2019
Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical ImpactHerbert A Mbunkah, Silvia Bertagnolio, Raph L Hamers, et al.
Journal of Virology|March 21, 2008
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infectionSusan J Little, Simon D W Frost, Joseph K Wong, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2000
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1C J Petropoulos, N T Parkin, K L Limoli, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavirZehava Grossman, Ellen E Paxinos, Diana Averbuch, et al.
Scientific Reports|May 29, 2024
Kinetics of SARS-CoV-2 infection biomarkers in a household transmission studyAna M Groh, Maria J G T Vehreschild, Damian Diaz, et al.
Journal of Virology|May 18, 2007
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populationsWei Huang, Susan H Eshleman, Jonathan Toma, et al.
Pageof 13